Skip to content

Clinical study on the treatment of uveal melanoma with plaque brachytherapy

Clinical study on the treatment of uveal melanoma with plaque brachytherapy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098173
Enrollment
Unknown
Registered
2025-03-04
Start date
2024-08-30
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uveal melanoma

Interventions

Test group:plaque brachytherapy

Sponsors

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 years and above, gender not limited, single eye disease not limited; 2. Clinical, pathological, or cytological diagnosis of uveal melanoma; 3. The distance between the posterior edge of the tumor and the optic disc is at least 3mm; No extraocular invasion; 4. When receiving this treatment, the maximum diameter of the tumor base is <= 19mm and the thickness is <= 10mm; 5. Voluntarily participate in this clinical trial and sign an informed consent form; 6. Willing to follow up and able to conduct follow-up according to the prescribed time;

Exclusion criteria

Exclusion criteria: 1. Exclusion of compliance: inability to comply with the study or belief by the researcher that they are unable to complete the study; 2. Patients with cranial diseases who cannot tolerate the side effects of radiation therapy; 3. Patients with systemic basic diseases that may seriously affect treatment, evaluation or compliance with the research scheme, including heart failure, respiratory failure, neurological or mental diseases (including alcohol or drug abuse), blood system diseases (coagulation dysfunction), immune system diseases (such as AIDS), infectious diseases (such as syphilis), malignant tumors or organ transplantation; 4. Patients with orbital deformities, a history of eye trauma, acute stage intraocular inflammation such as uveitis and keratitis, who are not suitable for periocular, retroocular or general anesthesia.

Design outcomes

Primary

MeasureTime frame
Enucleation rate;

Secondary

MeasureTime frame
overall survival;Recurrence rate;metastasis rate;median overall survival;Tumor control rate;Incidence of complications;Visual impairment rate;Effective visual acuity preservation rate;

Countries

China

Contacts

Public ContactXianqun Fan

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

drfanxianqun@126.com+86 21 53315587

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026